Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.

Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.

Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: The present invention provides diagnostic in vitro methods as well as kits and devices to be used in the methods of the present invention for diagnosis or prognosis of a pathologic condition characterized by the presence/absence of an endogenous hormone and/or hormone analog(s) thereof involved in diabetes or metabolic syndrome. The methods comprise a quantitative separation of at least those analytes of interest whose common presence interferes with measuring the presence/absence or concentration of one of the analytes of interest by a subsequent analytical method.

Abstract: The invention provides compositions and methods for determining GLP-1 analog and/or DPPIV inhibitor response in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, C-peptide, hsCRP, insulin, proinsulin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing GLP-1 analog and DPPIV inhibitor response. The invention also provides methods of treating a subject (e.g. one experiencing cardiodiabetes) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.

Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: The present invention provides diagnostic in vitro methods as well as kits and devices to be used in the methods of the present invention for diagnosis or prognosis of a pathologic condition characterized by the presence/absence of an endogenous hormone and/or hormone analog(s) thereof involved in diabetes or metabolic syndrome. The methods comprise a quantitative separation of at least those analytes of interest whose common presence interferes with measuring the presence/absence or concentration of one of the analytes of interest by a subsequent analytical method.

Abstract: The invention provides compositions and methods for determining insulin sensitizer drug response in a subject. The invention also provides compositions and methods for treating a subject according to insulin sensitizer drug response.

Abstract: The invention provides a kits, compositions and methods useful for determining atherosclerotic risk in a subject. In one aspect, the invention provides kit comprising a solid support comprising a capture probe set comprising a plurality of probes selected from (a) a probe selective for PTGS1, (b) a probe selective for PTGS2, (c) a probe selective for NOS3, (d) a probe selective for SERPINE1, (e) a probe selective for F5, (f) a probe selective for MTHFR, (g) a probe selective for ALOX5AP, (h) a probe selective for CETP, (i) a probe selective for APOE, (j) a probe selective for F2, (k) a probe selective for ACE, (l) a probe selective for LTA and (m) a probe selective for LPL.

Abstract: The invention provides compositions and methods for defining the state of atherosclerotic degeneration processes for the purposes of detection, severity assessment, monitoring and treatment. The states of atherosclerotic degeneration processes are identified by means of a biomarker panel particularly suited for detecting atherosclerotic degeneration processes. The simultaneous use of multiple markers with independent classification power will increase the performance of the panel in identifying atherosclerosis compared to other panels.

Abstract: The invention provides compositions and methods relating to a multiplex test which detects all relevant genetic risk markers associated with DPD deficiency in one single reaction test.

Abstract: The invention provides compositions and methods for characterizing appetite regulation in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, total ghrelin, obestatin, cholecystokinin, GLP-1(6-37)-NH2, NPY and ?-MSH. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing appetite regulation. The invention also provides methods of treating a subject (e.g. one experiencing obesity) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

Abstract: The invention provides compositions and methods for determining a subject's adipose tissue activity. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, resistin, PAI-1, optionally leptin and optionally visfatin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in identifying adipose tissue activity, which is associated with various disease states including chronic or systemic inflammation, atherosclerosis and other cardiovascular risks and complications. The invention also provides methods of treating a subject and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

Abstract: The invention provides compositions and methods for determining insulin efficacy in a subject. The invention also provides compositions and methods for treating a subject according to the efficacy of insulin in the subject.

Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.

Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.